Among current techniques for clinical genome editing, the CRISPR-associated gene editing system has emerged as a highly advantageous method to drive development of new gene and cell therapies. Through evolving routes of direct delivery of the CRISPR-ribonucleoprotein (RNP) complex, consisting of single guide RNA (sgRNA) and Cas nucleases, a non-viral approach has become increasingly in demand for gene-editing clinical trials. However, drug developers face significant challenges when initiating their clinical programs, which includes the design and production of the target-specific guides, the production of reliable, high-quality nucleases, and the ability to characterize the RNP complex for the efficient and safe delivery of a genomic therapy.

In this webinar, Oat Khodthong, PhD from Aldevron and Garrett Rettig, PhD from Integrated DNA Technologies (IDT) will highlight how our partnership and services will accelerate new CRISPR-based therapies to support genomic medicine. IDT will spotlight their capabilities in chemistry and oligo production for high-quality CRISPR gRNAs, while Aldevron will detail an expertise in cGMP CRISPR nuclease and RNP manufacturing and characterization*. We have brought our synergistic services together to provide drug development partners with complete CRISPR genome editing solutions.

Learning objectives from this webinar:

• IDT’s capability of manufacturing chemically-modified, high-quality guide RNAs
• Overview of the analytical testing to fully characterize the RNP complex
• Benefits of working with Aldevron and IDT for your CRISPR-RNP project

*Aldevron provides RNPs only to customers who are duly licensed, including to make and have made RNPs, for their intended use.